![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1623076
¼¼°èÀÇ Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå ±Ô¸ð : Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°, ¹üÀ§ ¹× ¿¹ÃøGlobal Anti-Neoplastic Agents Market Size By Product, By Application, By Geographic Scope And Forecast |
Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 1,257¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2030³â±îÁö 7.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 2,854¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°èÀÇ Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ´Ù¾çÇÑ ¿äÀο¡ ¿µÇâÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
¾Ï ÀÌȯÀ² Áõ°¡ :
Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀåÀº ¼¼°èÀÇ ¾Ï ÀÌȯÀ² »ó½Â¿¡ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Àα¸ÀÇ °í·ÉÈ, ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È, ȯ°æ ¿äÀÎ µîÀÇ °á°ú·Î ¾Ï ÀÌȯÀ²ÀÌ »ó½ÂÇϱ⠶§¹®¿¡ Ç׽Żý¹°Á¦ µîÀÇ È¿À²ÀûÀÎ ¾Ï Ä¡·á¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
¾Ï ¿¬±¸ÀÇ ÁøÀü :
Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå °³Ã´Àº ¾ÏÀÇ ºÐÀÚ »ý¹°ÇÐÀû ¿øÀÎ ±Ô¸í°ú ¸ÂÃã Ä¡·á¹ýÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ´Â µ¥ µû¸¥ °ÍÀÔ´Ï´Ù. ±âÁ¸ ÈÇпä¹ý¿¡ ºñÇØ Ç¥Àû¿ä¹ýÀº ºÎÀÛ¿ëÀÌ Àû°í º¸´Ù ÃÊÁ¡À» ¸ÂÃá Ä¡·á¹ýÀ» Á¦°øÇϱ⠶§¹®¿¡ »ç¿ë·üÀÌ Çâ»óµÇ°í ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
±â¼ú Áøº¸ :
Ç׾ǼºÁ¾¾çÁ¦ÀÇ ¾ÈÀü¼º°ú È¿´ÉÀº ¸®Æ÷¼Ø, ³ª³ëÀÔÀÚ, Å×ÀÏ·¯ ¸ÞÀ̵åÀÇ ¾à¹° Àü´Þ Ç÷§Æû µî ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ Áøº¸¿¡ ÀÇÇØ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ Ã¼°¨À̳ª Ä¡·á ¼ºÀûÀÇ Çâ»óÀ» ÅëÇØ¼, ÀÌ·¯ÇÑ ±â¼ú °³¹ßÀÌ ½ÃÀå °³Ã´À» ÁöÅÊÇϰí ÀÖ½À´Ï´Ù.
°Ç° °ü¸® ÁöÃâ È®´ë :
Ç׾ǼºÁ¾¾çÁ¦ µî ÃÖ÷´Ü ¾Ï Ä¡·áÀÇ Ã¤¿ëÀº ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼ÀÇ ÇコÄɾî ÁöÃâ Áõ°¡¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ Áö½ÄÀÇ Çâ»ó, º¸Çè Àû¿ë ¹üÀ§ÀÇ È®´ë, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â ¸ðµÎ, ÀÌ·¯ÇÑ Ä¡·á¸¦ º¸´Ù °¡±õ°Ô ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ÆÄÀÌÇÁ¶óÀÎ °³¹ß :
½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â °ÍÀº ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â Çõ½ÅÀûÀÎ Ç׾ǼºÁ¾¾çÁ¦ÀÇ °·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀÔ´Ï´Ù. Á¦¾à ±â¾÷À̳ª Çмú ±â°üÀº, ½Å±Ô ¹°ÁúÀ̳ª Ä¡·á ·¹Áö¸àÀÇ °³¹ß ¹× ½ÃÇèÀ» ÅëÇØ¼, Ä¡·á ¼±ÅÃÁöÀÇ Á¾·ù¸¦ Ç×»ó ´Ã¸®°í ÀÖ½À´Ï´Ù.
Ä¡·á ¼ºÀû Çâ»ó :
Ç¥Àû Ç׾ǼºÁ¾¾çÁ¦´Â À¯ÀüÀû üÁúÀ̳ª Á¾¾ç ¹ÙÀÌ¿À¸¶Ä¿ µîÀÇ È¯ÀÚÀÇ Æ¯Â¡À» °í·ÁÇÏ¿© Ä¡·á °èȹÀ» ¼¼¿ì´Â ¸ÂÃãÇü ÀÇ·áÀÇ °æÇâ¿¡ ÀÇÇØ ³ôÀº ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. °³º°È ±â¼úÀ» ÅëÇØ Ä¡·á ¼ºÀûÀÌ Çâ»óµÇ°í ºÎÀÛ¿ëµµ Àû¾îÁö±â ¶§¹®¿¡ ½ÃÀåÀº È®´ëµÇ°í ÀÖ½À´Ï´Ù.
±ÔÁ¦ ´ç±¹ Áö¿ø :
Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå °³Ã´Àº ÀǾàǰ °³¹ßÀ» °¡¼ÓÈÇϱâ À§ÇÑ ±ÔÁ¦ ÇÁ·Î±×·¥¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌ´Ï¼ÅÆ¼ºêÀÇ ¿¹·Î´Â ½ÂÀÎ ÇÁ·Î¼¼½ºÀÇ ½Å¼Óȳª Èñ±Í Áúº´¿ë ÀǾàǰ(Ofan Drug) ºÐ·ù¿¡ ´ëÇÑ Àμ¾Æ¼ºê µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. À¯¸ÁÇÑ ±ÔÁ¦ÀÇ Æ²Àº ½Å¾àÀÇ ½Å¼ÓÇÑ »ó¾÷ȸ¦ ÃËÁøÇÏ°í ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇÕ´Ï´Ù.
¼¼°è °í·ÉÈ :
Ç׾ǼºÁ¾¾çÁ¦¿¡ ´ëÇÑ ¿ä±¸´Â ƯÈ÷ ¼±Áø°ø¾÷±¹¿¡¼ ¾Ï ÀÌȯÀ² »ó½ÂÀÇ ¿øÀÎÀÌ µÇ´Â Àα¸ÀÇ °í·ÉÈ¿¡ ÀÇÇØ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. °í·ÉÀÚ´Â ¾Ï À§ÇèÀ» ³ôÀ̱â À§ÇØ Ä¡·áºñ¸¦ ¿Ã¸®°í ½ÃÀåÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
½ÅÈï °æÁ¦±¹ :
¶óƾ¾Æ¸Þ¸®Ä«, ¾ÆÇÁ¸®Ä«, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÅÈï ±¹°¡¿¡¼´Â Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀåÀÇ ¼ºÀå ¿©Áö°¡ ¸Å¿ì Å®´Ï´Ù. À̵é Áö¿ª¿¡¼´Â °¡Ã³ºÐ¼Òµæ Áõ°¡, ±Þ¼ÓÇÑ µµ½ÃÈ, ÇコÄɾî ÀÎÇÁ¶ó Á¤ºñ µîÀÇ ¿äÀÎÀ¸·Î ¼±ÁøÀûÀÎ ¾Ï Ä¡·á¸¦ º¸´Ù ³Î¸® ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ°í ÀÖ½À´Ï´Ù.
ÆÄÆ®³Ê½Ê ¹× Çù¾÷ :
Á¦¾à±â¾÷, Çмú±â°ü, ÀÇ·á±â°üÀÌ Á¦ÈÞÇÏ¿© ÀǾàǰ °³¹ß°ú »ó¾÷È ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÃßÁøÇÔÀ¸·Î½á ½ÃÀ尳ô¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÆÄÆ®³Ê½ÊÀº Á¤º¸ °øÀ¯, ÀÚ¿ø °øÀ¯, º¸¿Ï ±â¼ú¿¡ ´ëÇÑ Á¢±ÙÀ» ÃËÁøÇÔÀ¸·Î½á ½ÃÀå¿¡¼ Ç׾ǼºÁ¾¾çÁ¦ÀÇ °æÀï·ÂÀ» ³ôÀÔ´Ï´Ù.
¼¼°èÀÇ Ç׾ǼºÁ¾¾çÁ¦ ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
Ç׽Š»ý¹° ¾à¹° ½ÃÀåÀÇ °æ¿ì ¿©·¯ ¿äÀÎÀÌ ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ¶Ç´Â °úÁ¦·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. À̵鿡´Â ´ÙÀ½ÀÌ Æ÷ÇԵ˴ϴÙ. :
¾ö°ÝÇÑ ¹ý·ü :
¾ö°ÝÇÑ ¹ý·ü : Ç׾ǼºÁ¾¾çÁ¦ÀÇ ÆÇ¸Å ¹× ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ¹ý·üÀÌ ÀÖÀ¸¹Ç·Î Á¦Á¶¾÷ü´Â ½ÅÁ¦Ç° Ãâ½Ã°¡ Áö¿¬µÇ°Å³ª ºñ¿ëÀÌ Áõ°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù.
³ôÀº °³¹ß ºñ¿ë :
½Å±Ô Ç׾ǼºÁ¾¾çÁ¦ÀÇ °³¹ß¿¡´Â ´Ù¾×ÀÇ ¿¬±¸°³¹ßÀÌ ÇÊ¿äÇϸç, ´Ù¾×ÀÇ ºñ¿ëÀÌ µé °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÓ»ó ½ÃÇèÀÇ ½ÇÆÐÀ²·Î ÀÎÇØ Á¦¾à ±â¾÷ÀÇ ºñ¿ë ºÎ´ãÀº ´õ¿í Áõ´ëµË´Ï´Ù.
ƯÇã ²÷±â :
ÁÖ¿ä Ç׾ǼºÁ¾¾çÁ¦ÀÇ Æ¯Çã°¡ ¸¸·áµÇ¸é Á¦³×¸¯ ÀǾàǰÀÌ ½ÃÀå¿¡ ÁøÀÔÇÒ ¼ö ÀÖÀ¸¸ç °¡°ÝÀÌ Ç϶ôÇÏ°í ¼±¹ß Á¦Á¶¾÷ü ½ÃÀå Á¡À¯À²ÀÌ ¶³¾îÁý´Ï´Ù.
ºÎÀÛ¿ë :
Ç׾ǼºÁ¾¾çÁ¦´Â È¿°úÀûÀÌÁö¸¸ ¸Þ½º²¨¿ò, ±¸Åä, Å»¸ð, ¸é¿ª¾ïÁ¦ µî ½É°¢ÇÑ ºÎÀÛ¿ëÀ» ¼ö¹ÝÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎÀÛ¿ëÀ» °ÆÁ¤ÇÑ ³ª¸ÓÁö, ÀÇ»çÀÇ Ã³¹æÀ²À̳ª ȯÀÚÀÇ ÄÄÇø®¾ð½º°¡ Á¦ÇÑµÉ ¼öµµ ÀÖ½À´Ï´Ù.
³»¼º °³¹ß :
½Ã°£ÀÌ Áö³²¿¡ µû¶ó Á¾¾ç ¼¼Æ÷´Â Ç׾ǼºÁ¾¾çÁ¦¿¡ ´ëÇÑ ³»¼ºÀ» ȹµæÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÇöÀç Ä¡·á¹ýÀÇ È¿´ÉÀÌ ¶³¾îÁö°í »õ·Î¿î Ä¡·á¹ýÀÇ °³¹ßÀÌ ÇÊ¿äÇÕ´Ï´Ù.
°Ç° °ü¸®¿¡ ´ëÇÑ ¾×¼¼½º Á¦ÇÑ :
ƯÁ¤ Áö¿ª, ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼´Â ÀÇ·á±â°ü¿¡ ´ëÇÑ Á¢±Ù ºÎÁ·°ú °úµµÇÑ Ä¡·áºñ·Î ÀÎÇØ ȯÀÚ°¡ Ç׾Ǽº Á¾¾çÁ¦¸¦ »ç¿ëÇÏ´Â °ÍÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.
±â¼úÀûÀÎ ¾î·Á¿ò :
¾ÈÀü¼º°ú È¿´ÉÀ» Çâ»ó½ÃŲ ½Å±Ô Ç׾ǼºÁ¾¾çÁ¦ÀÇ °³¹ß¿¡´Â ±â¼úÀûÀÎ ¾î·Á¿òÀÌ ¼ö¹ÝµÇ¾î, ´Ù¾×ÀÇ ¿¬±¸°³¹ßºñ°¡ ÇÊ¿äÇÕ´Ï´Ù.
´ëü ¿ä¹ý°úÀÇ °æÀï :
¸é¿ª¿ä¹ý°ú Ç¥Àû¿ä¹ýÀº ¾ÏÄ¡·á¿¡¼ Á¡Á¡ º¸±ÞµÇ°í ÀÖ´Â 2°¡Áö ´ëü¿ä¹ýÀÔ´Ï´Ù. ±âÁ¸ÀÇ Ç׾ǼºÁ¾¾çÁ¦´Â ±× À¯È¿¼º°ú ÀÔ¼ö °¡´É¼ºÀÌ ³ô¾ÆÁö°í Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ ´ëü ¿ä¹ý°úÀÇ °æÀï¿¡ Á÷¸éÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
Anti-Neoplastic Agents Market size was valued at USD 125.71 Billion in 2023 and is projected to reach USD 285.49 Billion by 2030 , growing at a CAGR of 7.1% during the forecasted period 2024 to 2030.
Global Anti-Neoplastic Agents Market Drivers
The market drivers for the Anti-Neoplastic Agents Market can be influenced by various factors. These may include:
Growing Cancer Incidence:
The market for anti-neoplastic agents is significantly influenced by the rising incidence of cancer worldwide. The need for efficient cancer treatments, such as anti-neoplastic drugs, is increasing as cancer rates rise as a result of ageing populations, changing lifestyles, and environmental factors.
Progress in Cancer Research:
The market for anti-neoplastic drugs is expanding due to ongoing efforts to better understand the molecular causes of cancer and to develop tailored treatments. Compared to conventional chemotherapy, targeted therapies provide more focused treatment options with fewer side effects, which has improved usage and expanded the market.
Technological Advancements:
The safety and effectiveness of anti-neoplastic drugs are improved by advances in drug delivery systems, including as liposomes, nanoparticles, and tailored drug delivery platforms. Through bettering patient experiences and treatment outcomes, these technology developments support market expansion.
Growing Healthcare Expenditure:
The adoption of cutting-edge cancer treatments, such as anti-neoplastic drugs, is supported by rising healthcare spending, especially in developing nations. Increased patient knowledge, insurance coverage expansions, and government initiatives all help to make these treatments more accessible.
Pipeline Development:
The market's expansion is fueled by a strong pipeline of innovative anti-neoplastic drugs that target different types of cancer. The variety of therapeutic alternatives is constantly being increased by pharmaceutical corporations and academic institutions through the development and testing of novel substances and treatment regimens.
Improved Treatment Outcomes:
Targeted anti-neoplastic drugs are in high demand due to the trend towards personalized medicine, in which patient features such as genetic makeup and tumor biomarkers are taken into account when designing a treatment plan. The market is expanding because personalized techniques result in better treatment outcomes and fewer side effects.
Regulatory Support:
Market access for anti-neoplastic drugs is facilitated by regulatory programmes that aim to accelerate drug development. Examples of these initiatives include faster approval processes and incentives for orphan drug classification. Promising regulatory frameworks facilitate the expeditious commercialization of novel medicines, hence propelling market expansion.
Global Ageing Population:
The need for anti-neoplastic medications is driven by the ageing population, especially in industrialized nations where it is a contributing factor to the rising incidence of cancer. Due to their increased cancer risk, older persons are driving up treatment costs and expanding the market.
Emerging Economies:
The market for anti-neoplastic drugs has enormous room to grow in emerging economies in Latin America, Africa, and Asia-Pacific. Advanced cancer treatments are more widely accessible in these areas due to factors like rising disposable incomes, rapid urbanization, and improved healthcare infrastructure.
Partnerships and Collaborations:
Pharmaceutical corporations, academic institutions, and healthcare organizations work together to expedite medication development and commercialization initiatives, which in turn spurs market expansion. Partnerships increase the competitiveness of anti-neoplastic agents in the market by facilitating information sharing, resource sharing, and access to complementary technologies.
Global Anti-Neoplastic Agents Market Restraints
Several factors can act as restraints or challenges for the Anti-Neoplastic Agents Market. These may include:
Strict laws:
Manufacturers may have difficulties as a result of the strict laws governing the marketing and approval of anti-neoplastic drugs, which could cause delays in the launch of new products and higher expenses.
High Development Costs:
Developing novel anti-neoplastic drugs requires a significant amount of research and development, which can be expensive. Furthermore, the cost burden on pharmaceutical businesses is further increased by the failure rate in clinical trials.
Patent Expiration:
When major anti-neoplastic medications' patents expire, generic competitors might join the market, driving down prices and eroding market share for the original producers.
Side Effects:
Anti-neoplastic drugs, although effective, frequently have serious side effects such as nausea, vomiting, hair loss, and immunosuppression. Physician prescription rates and patient compliance may be restricted due to worries about these negative effects.
Resistance Development:
Over time, tumor cells may become resistant to anti-neoplastic drugs, which will decrease the efficacy of current therapies and call for the creation of new ones.
Limited Access to Healthcare:
In certain areas, especially in developing nations, patients' access to anti-neoplastic drugs may be restricted by a lack of access to healthcare facilities and excessive treatment expenses.
Technological Difficulties:
Creating novel anti-neoplastic drugs with enhanced safety and efficacy profiles presents technological difficulties that call for hefty expenditures in R&D.
Competition from Alternative Therapies:
Immunotherapy and targeted therapy are two alternative therapies that are becoming more and more popular in the treatment of cancer. Traditional anti-neoplastic drugs may face competition from these alternatives due of their growing efficacy and availability.
The Global Anti-Neoplastic Agents Market is segmented on the basis of Product, Application, And Geography.
Based on the Product, the market is bifurcated into Chemotherapeutic Agents Biological/Immunotherapeutic Agents and Personalized Medicine. Chemotherapeutic agents are predicted to hold the largest market share due to the ease of availability of drugs. Immunotherapeutic agents will grow with the highest CAGR owing to the growing acceptance of biological therapy as they have lesser side effects.
Based on the Application, the market is bifurcated into Hospitals, Clinics, Cancer Rehabilitation Centers, and Ambulatory Surgical Centers. Hospitals are anticipated to hold the maximum share as there is a vast number of cancer patients hospitalized in the hospitals every year. As per the statistics given by The Healthcare Cost and Utilization Project (H-cup), there were 4.7 Mn hospitalizations related to cancer in the U.S. in the year 2009 and about 6% of adult inpatient hospital cost was generated by the hospitalization of cancer patients.